Abstract: Polymers comprising a ligand containing a carboxylic acid group, optionally at least one ion of an element of the atomic numbers 21-29, 42, 44 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides are valuable complexing agents and complexes for diagnosis.

Abstract: Porphyrin complex compounds consisting of a meso-tetraphenylporphyrin ligand of general formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 have varying meanings, and an ion of an element of atomic numbers 21-32, 38, 39, 42-51 or 58-83 as well as optionally one or more physiologically harmless cation(s) of inorganic and/or organic bases, amino acids or amino acid amides are valuable diagnostic agents.

Abstract: The invention relates to a process for the production of C-substituted diethylenetriamines of general formula ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have different meanings.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: A diagnostic medium contains at least one physiologically well tolerated complex salt comprising an anion of a complexing acid and one or more central ion or ions of an element with an atomic number of 21 to 29, 42, 44 or 57 to 83 and, optionally, one or more physiologically biocompatible cation or cations of an inorganic and/or organic base or amino acid, optionally, with additives customary in galenic formulations, dissolved or suspended in an aqueous medium.

Abstract: A diagnostic medium contains at least one physiologically well tolerated complex salt comprising an anion of a complexing acid and one or more central ion or ions of an element with an atomic number of 21 to 29, 42, 44 or 57 to 83 and, optionally, one or more physiologically biocompatible cation or cations of an inorganic and/or organic base or amino acid, optionally, with additives customary in galenic formulations, dissolved or suspended in an aqueous medium.

Abstract: A diagnostic medium contains at least one physiologically well tolerated complex salt comprising an anion of a complexing acid and one or more central ion or ions of an element with an atomic number of 21 to 29, 42, 44 or 57 to 83 and, optionally, one or more physiologically biocompatible cation or cations of an inorganic and/or organic base or amino acid, optionally, with additives customary in galenic formulations, dissolved or suspended in an aqueous medium.

Abstract: 1. Compounds of general Formula I ##STR1## wherein n and m in each case mean the numbers 0, 1, 2, 3 and 4,X stands for a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,R.sup.1 and R.sup.2, being different, mean in each case a hydrogen atom or a straight-chain, branched, saturated or unsaturated C.sub.0 -C.sub.20 -alkylene group which optionally contains imino, phenylenoxy, phenylenimino, amido, hydrazido, ester group(s), oxygen, sulfur and/or nitrogen atom(s) and is substituted, if desired, by hydroxy, mercapto, imino, epoxy, oxo, thioxo and/or amino group(s), this alkylene group exhibiting at the end either a second molecule of general Formula I.sub.A or I.sub.B ##STR2## a functional group, or, linked by way of this functional group, a bio- or macromolecule,are valuable diagnostic and therapeutic media.

Abstract: Compounds of the general formula I: ##STR1## wherein R.sup.1 signifies a COOX group or the group ##STR2## R.sup.2 and R.sup.3 are the same or different and signify a hydrogen atom, a lower straight- or branched-chain, hydrocarbon radical, a phenyl or benzyl group or either R.sup.2 or R.sup.3 signifies the group ##STR3## or R.sup.2 or R.sup.3 together signify a trimethylene or tetramethylene radical, R.sup.4 represents a straight- or branched-chain mono- or poly-hydroxyalkyl radical, R.sup.5 represents a hydrocarbon atom, a lower straight- or branched-chain, optionally mono- or poly-hydroxylated, hydrocarbon radical, Q signifies an oxygen or sulfur atom or the group ##STR4## and X represents hydrogen atoms and/or metal ion equivalents, and their salts with physiologically harmless organic bases, are valuable complexing agents, complexes and complex salts for diagnostic imaging.

Abstract: A new process for the production of mono-N-substituted tetraaza macrocycles, N-substituted-tri-N-carboxyalkyl tetraaza macrocycles, and/or metal complexes thereof is described.

Abstract: The macrocyclic compounds of the following formula I and IV, defined herein and their salts with inorganic and/or organic bases, amino acids or amino acid amides are valuable diagnostic and therapeutic agents.

Abstract: Complex compounds of general Formula I ##STR1## wherein X is a hydrogen atom and/or a metal ion equivalent of at least one element of atomic numbers 21-29, 42, 44 or 58-70, with at least two of the substituents X representing a metal ion equivalent, andR.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and n are defined herein, as well as their salts with organic and/or inorganic bases, are valuable compounds for organ-specific NMR diagnostics.

Abstract: A process for the production of N-.beta.-hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and N-.beta.-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetrade cane derivatives and their metal complexes is described.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: A diagnostic medium contains at least one physiologically well tolerated complex salt comprising an anion of a complexing acid and one or more Gadolinium ions and, optionally, one or more physiologically biocompatible cation or cations of an inorganic and/or organic base or amino acid, optionally, with additives customary in galenic formulations, dissolved or suspended in an aqueous medium.

Abstract: The macrocyclic compounds of the following formula I and IV, defined herein and their salts with inorganic and/or organic bases, amino acids or amino acid amides are valuable diagnostic and therapeutic agents.

Abstract: Compounds of the general formula I: ##STR1## R.sup.1 signifies a COOX group or the group ##STR2## R.sup.2 and R.sup.3 are the same or different and signify a hydrogen atom, a lower straight- or branched-chain, hydrocarbon radical, a phenyl or benzyl group or either R.sup.2 or R.sup.3 signifies the group ##STR3## or R.sup.2 or R.sup.3 together signify a trimethylene or tetramethylene radical, R.sup.4 represents a straight- or branched-chain mono- or poly-hydroxyalkyl radical, R.sup.5 represents a hydrocarbon atom, a lower straight- or branched-chain, optionally mono- or poly-hydroxylated, hydrocarbon radical, Q signifies an oxygen or sulfur atom or the group ##STR4## wherein j signifies the numbers 1 to 4 and R.sup.

Abstract: Porphyrin complex compounds, consisting of a mesotetraphenylporphyrin ligand, optionally at least one ion of an element with atomic numbers 13, 21, 32, 37-39, 42-44, 49, 50 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable diagnostic and therapeutic agents.

Abstract: Tetraazacyclododecane compounds of general formula I ##STR1## in which E and Q are defined herein and their salts with inorganic and/or organic bases, amino acids or amino acid amides are valuable pharmaceutical agents.

Abstract: Porphyrin complex compounds consisting of at least one porphyrin ligand, optionally at least one ion of an element of atomic numbers 5, 13, 21-32, 37-39, 42-44, 49, 50 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable diagnostic media and therapeutic agents.